NVRO Stock Recent News

Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.

Nevro Corp. (NYSE:NVRO ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal - CEO and President Rod MacLeod - Chief Financial Officer Conference Call Participants Nathan Treybeck - Wells Fargo Anthony Petrone - Mizuho Carolyn Huszagh - Bank of America Justin Lin - William Blair Bradley Bowers - Mizuho Securities Operator Good afternoon. My name is Audra, and I will be your conference operator today.

Nevro (NVRO) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $0.98 per share a year ago.

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.

Despite convincing beats on its latest set of quarterly figures, the market wasn't all that impressed with the company's latest developments.

Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.

Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript

Nevro (NVRO) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.54 per share a year ago.

Nevro's (NVRO) latest announcement of a positive coverage update from Carelon Healthcare for PDN treatment is likely to serve a wider patient pool.